SelectQuote (SLQT) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
5 Feb, 2026Executive summary
Revenue for Q2 FY2026 reached $537.1 million, up 12% year-over-year, led by strong Healthcare Services and Life segment growth, with Senior segment showing modest gains and near-record 39% EBITDA margins.
Adjusted EBITDA for Q2 FY2026 was $84.7 million, slightly down from the prior year due to PBM reimbursement headwinds and external partner decisions.
Net income for Q2 FY2026 was $69.3 million, up from $53.2 million in the prior year, while net income attributable to common shareholders was $51.2 million.
Entered a multi-year PBM agreement and secured a new $415 million credit facility, extending debt maturities to 2031 and enhancing capital flexibility.
Fiscal 2026 guidance was reduced by $40 million due to a national carrier's marketing budget cut and PBM reimbursement changes.
Financial highlights
Consolidated revenue for Q2 FY2026 was $537.1 million, with net income of $69.3 million and Adjusted EBITDA of $84.7 million.
Senior segment revenue grew 2% to $261.5 million, with Adjusted EBITDA of $102.5 million and a 39% margin.
Healthcare Services revenue increased 26% year-over-year to $230.7 million, with SelectRx membership up 17% to 113,483.
Life segment revenue rose 9% to $43.6 million, with final expense premiums up 24% and Adjusted EBITDA of $5.6 million.
Operating cash flow for the six months ended December 31, 2025, was negative $21.6 million, an improvement from the prior year.
Outlook and guidance
Fiscal 2026 consolidated revenue guidance revised to $1.61–$1.71 billion and Adjusted EBITDA to $90–$100 million, reflecting $40 million in aggregate headwinds.
Operating cash flow for fiscal 2026 expected at $25–$35 million, up over $40 million at midpoint from last year.
Senior division targets 20%+ EBITDA margins; Healthcare Services aims for $40–$50 million annualized Adjusted EBITDA exit rate.
Membership in Healthcare Services expected to end fiscal 2026 flat to modestly down, but with 20%+ year-over-year revenue growth.
Guidance revision attributed to external factors, not internal performance.
Latest events from SelectQuote
- FY2024 revenue and EBITDA beat guidance; 2025 growth limited by capital, but outlook strong.SLQT
Q4 202420 Jan 2026 - Revenue up 26% with strong pharmacy growth; $100M securitization boosts capital flexibility.SLQT
Q1 202517 Jan 2026 - Q2 revenue up 19% to $481.1M, net income $53.2M, $350M equity investment secured.SLQT
Q2 202523 Dec 2025 - All proposals passed, including director elections and auditor ratification, with no shareholder questions.SLQT
AGM 202516 Dec 2025 - Board recommends approval of all 2025 meeting proposals, emphasizing performance and governance.SLQT
Proxy Filing1 Dec 2025 - Board recommends approval of all proposals, highlighting governance and pay-for-performance.SLQT
Proxy Filing1 Dec 2025 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.SLQT
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with board support for all.SLQT
Proxy Filing1 Dec 2025 - Q3 FY2025 revenue up 8% to $408.2M; SelectRx and Life growth offset Senior declines.SLQT
Q3 202526 Nov 2025